ABCC10 Plays a Significant Role in the Transport of Gefitinib and Contributes to Acquired Resistance to Gefitinib in NSCLC

• Váldodahkkit: Hongbo Zhao (Dahkki), Yutang Huang (Dahkki), Jingjing Shi (Dahkki), Yi Dai (Dahkki), Lanxiang Wu (Dahkki), Honghao Zhou (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Frontiers Media S.A., 2018-11-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Gefitinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (EGFR-TKI), is used clinically as first-line therapy in patients with advanced non-small cell lung cancer (NSCLC) with EGFR activating mutations, but the inevitable development of acquired resistance limits its efficacy....